Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

165 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
FGF21-based pharmacotherapy--potential utility for metabolic disorders.
Gimeno RE, Moller DE. Gimeno RE, et al. Among authors: moller de. Trends Endocrinol Metab. 2014 Jun;25(6):303-11. doi: 10.1016/j.tem.2014.03.001. Epub 2014 Apr 5. Trends Endocrinol Metab. 2014. PMID: 24709036 Review.
Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity.
Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, Zierath JR, Chibalin AV, Moller DE, Kharitonenkov A, Krook A. Mashili FL, et al. Among authors: moller de. Diabetes Metab Res Rev. 2011 Mar;27(3):286-97. doi: 10.1002/dmrr.1177. Diabetes Metab Res Rev. 2011. PMID: 21309058
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE. Gaich G, et al. Among authors: moller de. Cell Metab. 2013 Sep 3;18(3):333-40. doi: 10.1016/j.cmet.2013.08.005. Cell Metab. 2013. PMID: 24011069 Free article. Clinical Trial.
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.
Kharitonenkov A, Beals JM, Micanovic R, Strifler BA, Rathnachalam R, Wroblewski VJ, Li S, Koester A, Ford AM, Coskun T, Dunbar JD, Cheng CC, Frye CC, Bumol TF, Moller DE. Kharitonenkov A, et al. Among authors: moller de. PLoS One. 2013;8(3):e58575. doi: 10.1371/journal.pone.0058575. Epub 2013 Mar 11. PLoS One. 2013. PMID: 23536797 Free PMC article.
Fibroblast growth factor 21 corrects obesity in mice.
Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Coskun T, et al. Among authors: moller de. Endocrinology. 2008 Dec;149(12):6018-27. doi: 10.1210/en.2008-0816. Epub 2008 Aug 7. Endocrinology. 2008. PMID: 18687777
Identification and characterization of a major liver lysophosphatidylcholine acyltransferase.
Zhao Y, Chen YQ, Bonacci TM, Bredt DS, Li S, Bensch WR, Moller DE, Kowala M, Konrad RJ, Cao G. Zhao Y, et al. Among authors: moller de. J Biol Chem. 2008 Mar 28;283(13):8258-65. doi: 10.1074/jbc.M710422200. Epub 2008 Jan 14. J Biol Chem. 2008. PMID: 18195019
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Among authors: moller de. Diabetes Care. 2016 Jul;39(7):1241-9. doi: 10.2337/dc15-1643. Epub 2015 Dec 17. Diabetes Care. 2016. PMID: 26681715 Clinical Trial.
Metabolic disease drug discovery- "hitting the target" is easier said than done.
Moller DE. Moller DE. Cell Metab. 2012 Jan 4;15(1):19-24. doi: 10.1016/j.cmet.2011.10.012. Cell Metab. 2012. PMID: 22225873 Free article.
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Heine RJ, Fu H, Kendall DM, Moller DE. Heine RJ, et al. Among authors: moller de. Diabetes. 2013 Oct;62(10):e16-7. doi: 10.2337/db13-0690. Diabetes. 2013. PMID: 24065798 Free PMC article. No abstract available.
Metabolic syndrome: a clinical and molecular perspective.
Moller DE, Kaufman KD. Moller DE, et al. Annu Rev Med. 2005;56:45-62. doi: 10.1146/annurev.med.56.082103.104751. Annu Rev Med. 2005. PMID: 15660501 Review.
165 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback